89bio reports positive data from Phase 1 clinical trial of BIO89-100
Category: #health  By Mateen Dalal  Date: 2019-05-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

89bio reports positive data from Phase 1 clinical trial of BIO89-100

A clinical-stage biopharmaceutical company, 89bio LTD that focusses on NASH (nonalcoholic steatohepatitis), liver and other metabolic disorders, recently announced positive results from Phase 1 SAD (single ascending dose) study on healthy volunteers of its investigational medicine, BIO89-100. The investigational medicine (BIO89-100) is a long acting glycopegylated FGF21 (fibroblast growth factor 21) analogue for treatment of patients with nonalcoholic steatohepatitis, reports source.

Hank Mansbach, Managing Director & Chief Medical Officer, 89bio said that there were consistent results from preclinical studies of BIO89-100 in its first in-human trial. In the study, the investigational medicine confirmed a favorable safety and a biomarker profile with an enduring response with a single dose. It has been expected that these findings will support weekly and 2-week subcutaneous dosing.

The medicine had robust pharmacodynamic effects across multiple lipid parameters, provided the subjects were healthy volunteers with lipid parameters in the normal range, Mansbach added.

Reportedly, BIO89-100 was mostly safe and well tolerated according to its Phase 1 study. The commonly observed adverse events were headache and injection-site reactions, which were mild. The PK (pharmacokinetic) profile of the medicine was generally a dose proportional with a half-life ranging from 53-100 hours, approximately. At single doses of 9.1 mg or higher, the medicine shows significant improvements as compared to baseline in key lipid parameters, measured at 8 & 15 days. The mean changes in comparison to baseline include decline in triglycerides up to 51% and LDL-C up to 37% along with increase in HDL-C up to 36%.

Rohan Palekar, Chief Executive Officer, 89bio, was reportedly quoted saying that the data from the experiment support the advancement of BIO89-100 in study of patients with liver disease, to assess its potential to address the complex nature of nonalcoholic steatohepatitis.

As per sources close to the matter, the first in-human trial of Bio89-100 was double-blind, single ascending dose study designed, randomized & placebo-controlled to evaluate safety, PK profile, tolerability & immunogenicity. It was tested on 58 healthy adult volunteers.

Source credits: https://www.prnewswire.com/news-releases/89bio-reports-positive-top-line-data-from-phase-1-single-ascending-dose-clinical-trial-of-bio89-100-an-investigational-medicine-for-nash-300854790.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
By Mateen Dalal

NantHealth, Inc., a personalized, evidence-based, next-generation healthcare company and NantOmics, LLC, one of the leading companies in molecular analysis, have reportedly launched an innovative AI platform for assisting pathologists in image-based ...

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...